Rafivirumab
Rafivirumab
Rafivirumab (pronunciation: rah-fee-vi-roo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that works by blocking the growth of new blood vessels, thereby starving the cancer cells of the nutrients they need to grow.
Etymology
The name "Rafivirumab" is derived from the Latin words "rafi", meaning "to heal", and "virumab", a common suffix for monoclonal antibodies.
Mechanism of Action
Rafivirumab works by binding to a protein called vascular endothelial growth factor (VEGF). This protein plays a key role in the formation of new blood vessels. By blocking VEGF, Rafivirumab can prevent the growth of new blood vessels, thereby starving the cancer cells of the nutrients they need to grow.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Vascular endothelial growth factor (VEGF): A protein that stimulates the formation of blood vessels.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer, infections, and other diseases.
See Also
External links
- Medical encyclopedia article on Rafivirumab
- Wikipedia's article - Rafivirumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski